Clinical trials: Clinical High Risk for Psychosis
Clinical High Risk for Psychosis
Glutamate Reducing Interventions in Schizophrenia
Participants will be administered several doses of pomaglumetad (POMA) (low and high doses) over 14 days to individuals at clinical high risk for developing psychosis and use magnetic resonance imaging (MRI) brain imaging to…
- Trial name
- NCT03321617
- Testing
- Pomaglumetad methionil
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- New York State Psychiatric Institute
Psychosis, First Episode Psychosis
Feasibility of an Early Detection Program for Early Psychosis on a College Campus
The objective of the proposed study is to determine the feasibility of an Early Detection program that aims to: (i) identify college students at clinical high risk (CHR) of psychosis or with first episode psychosis (FEP), and…
- Conditions
- Psychosis, First Episode Psychosis, Clinical High Risk for Psychosis
- Trial name
- NCT03983421
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- University of New Mexico
Clinical High Risk for Psychosis
Gabapentin in Patients at Clinical Risk for Psychosis
The purpose of this study is to test the effects of the drug gabapentin on brain function thought to be important in the development of schizophrenia.
- Trial name
- NCT02557945
- Testing
- Gabapentin
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- New York State Psychiatric Institute
Psychosis
Developing Clinical Tools to Communicate Genetic Risk for Individuals Who Are Clinical High Risk for Psychosis
While great strides are being made in identifying early signs that place people at a 'high risk state' for different illness conditions, at the same time, advances are being made in the identification of genes associated with…
- Trial name
- NCT04325568
- Testing
- PsyGist and Clinician Manual
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- New York University